Avacta RNS releases

Avacta building on 'significant' commercial momentum for Affimer technology

Dr Alastair Smith, chief executive of Avacta Group Plc ( LON:AVCT ), tells Proactive they've been making significant technical and commercial headway with their Affimer technology, as part of the firm's trading update for the year to the end of July 2017. ''It's been 12 months of significant de-risking of the therapeutic...

Avacta CEO Dr Alastair Smith 'encouraged' by first commercial Affimer deal

Dr Alastair Smith, chief executive of Avacta Group Plc ( LON:AVCT ) tells Proactive they're at an “important value inflection point” after validating the commercial potential of its Affimer technology. It follows the successful evaluation of its technology by a “large, global diagnostics developer”. This has led the partner...

Avacta Group boss talks through 'excellent' Affimer study results

Avacta Group Plc ( LON:AVCT ) has described as “excellent” results from the latest study of its Affimer technology, which it said is now at an “inflection point” as a therapeutic platform. Chief Executive Dr Alastair Smith tells Proactive he's delighted with the results which show that none of the Affimer scaffolds induce a...

Pages